triflusal qualitec 300 mg capsulas duras efg
qualitec europa, s.l. - triflusal - excipientes: - agentes antitrombÓticos - inhibidores de la agregación plaquetaria, excluyendo heparina - triflusal
triflusal toll manufacturing services 300 mg capsulas efg
toll manufacturing services, s.l. - triflusal - excipientes: - agentes antitrombÓticos - inhibidores de la agregación plaquetaria, excluyendo heparina - triflusal
anpeval 300 mg capsulas duras efg
industria quimica y farmaceutica vir s.a. - triflusal - cÁpsula dura - 300 mg - triflusal 300 mg - triflusal
disgren 300 mg cápsulas duras
laboratorios ern s.a. - triflusal - cÁpsula dura - 300 mg - triflusal 300 mg - triflusal
disgren 600 mg polvo y disolvente para solucion oral
laboratorios ern s.a. - triflusal - polvo y disolvente para soluciÓn oral - 600 mg - triflusal 600 mg - triflusal
lonsurf
les laboratoires servier - trifluridine, tipiracil clorhidrato de - neoplasias colorrectales - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
tipiracilo clorhidrato/trifluridina 20/8,19 comprimidos recubiertos
laboratorios elea chile s.p.a. - tipiracilo clorhidrato;trifluridina - tipiracilo clorhidrato 9,42 mg núcleo; trifluridina 20 mg núcleo - en el tratamiento de pacientes adultos con cáncer colorrectal metastásicoque hayan recibido tratamientos previos o que no sean considerados aptos para el tratamiento con terapias disponibles incluyendo quimioterapia basada en fluoropirimidinas, oxalaplatino e irinotecan, agentes anti-receptor egf y anti-vegf.
triflusal ratiopharm 300mg 30 capsulas efg
triflusal ratiopharm 300mg 50 capsulas efg
triflusal teva 300mg 50 capsul efg